Compare Incyte Corporation (INCY) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NRG Energy Inc — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while NRG Energy Inc trades at $133.36 (market cap $27.55B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.46% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NRG | |
|---|---|---|
Market Cap | $23.11B | $27.55B |
Sector | Health | Utilities |
52-Week High | $118.52 | $184.03 |
52-Week Low | $67.38 | $120.65 |
Enterprise Value | $19.13B | $51.38B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NRG Energy trades at $131.02, up 1.48% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth to $30.71B but thin net margins of 0.74%. Analyst consensus remains bullish with a $196.33 price target, representing 50% upside potential from current levels. Recent news highlights expanding generation capacity and data center deals as growth catalysts.
The outlook balances strong analyst support against elevated valuation multiples and technical weakness. Key opportunities include power demand growth and strategic positioning, while risks involve margin pressure and debt levels exceeding 56% of assets. The upcoming Q2 2026 earnings report on August 4 will be critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
